Ignite Creation Date:
2024-05-06 @ 7:49 PM
Last Modification Date:
2024-10-26 @ 3:14 PM
Study NCT ID:
NCT06147895
Status:
COMPLETED
Last Update Posted:
2024-03-25
First Post:
2023-11-15
Brief Title:
A Study to Evaluate the Safety Reactogenicity and Immunogenicity of Prophylactic Hepatitis B Vaccine
Sponsor:
CHA Vaccine Institute Co Ltd
Organization:
CHA Vaccine Institute Co Ltd
Study Overview
Official Title:
A Randomized Open-labelled Parallel Phase 1 Clinical Study to Evaluate the Safety Reactogenicity and Immunogenicity of the Hepatitis B Vaccine CVI-HBV-002 in Adults
Status:
COMPLETED
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CVI-HBV-002
Brief Summary:
The purpose of this study is to evaluate the safety and immunogenicity of the investigational medicinal product CVI-HBV-002
Detailed Description:
A Randomized Open-labelled Parallel Phase 1 clinical study to evaluate the safety reactogenicity and immunogenicity of the hepatitis B vaccine CVI-HBV-002 in adults
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None